Skip to main content

Published locations for REACH2: Ruxolitinib outperformed control treatment for refractory acute GVHD

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. REACH2: Ruxolitinib outperformed control treatment for refractory acute GVHD

User login

  • Reset your password
  • /content/reach2-ruxolitinib-outperformed-control-treatment-refractory-acute-gvhd
  • /hematologynews/article/221169/transplant/reach2-ruxolitinib-outperformed-control-treatment
  • /internalmedicinenews/article/221169/transplant/reach2-ruxolitinib-outperformed-control-treatment
  • /oncologypractice/article/221169/transplant/reach2-ruxolitinib-outperformed-control-treatment
  • /hematology-oncology/article/221169/transplant/reach2-ruxolitinib-outperformed-control-treatment
  • /hematologytimes/article/221169/transplant/reach2-ruxolitinib-outperformed-control-treatment
  • /internalmedicine/article/221169/transplant/reach2-ruxolitinib-outperformed-control-treatment